Ethical Issues of Using Gene Therapy in the Treatment of AMD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNantes University Hospital
About this trial
The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with exsudative AMD, male female >18 years Patients for whom the doctor could consider gene therapy.
Disqualifiers
None
Trial population
exsudative AMD patients in o\^pthalmology department in CHU Nantes
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The experience and current treatment outcomes perceived by patients
Semi-structured interviews
Time frame
1 monthsSecondary outcomes
1
Patients' perceptions, expectations, and potential concerns regarding gene therapy
Semi-structured interviews
Time frame
1 month2
Patients' perception and representation of decisional autonomy in their health decisions
Semi-structured interviews
Time frame
1 monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov